Literature DB >> 27134857

Ischemia Modified Albumin (IMA) - A Marker of Glycaemic Control and Vascular Complications in Type 2 Diabetes Mellitus.

Rajinder Chawla1, Rinchu Loomba2, Deepak Guru3, Vikas Loomba4.   

Abstract

INTRODUCTION: Ischemia modified albumin (IMA) has emerged as a marker for ischemic injury and oxidative damage, particularly in myocardial infarction. There are very few studies on the significance of IMA in other conditions associated with ischemia. The complications of diabetes mellitus (DM) arising out of poor glycaemic control have an underlying ischemic aetiology. AIM: To evaluate correlation of IMA with glycaemic control in type 2 DM (T2DM). Secondary aim was to assess the utility of IMA as a marker for vascular complications in T2DM.
MATERIALS AND METHODS: During this cross-sectional study, a total of 100 diagnosed cases of T2DM were recruited between May 2013 and September 2013. The IMA, HbA1c, lipid profile, creatinine and urine micro-albumin levels were measured and analysed with respect to clinical condition of the patients. STATISTICAL ANALYSIS: The epidemiological software, Epi-Info 7.1.5, was used for the statistical analysis, p-value<0.05 was defined as level of significance.
RESULTS: The study subjects were in the age group from 30 to 75 years and 52.4% were males. There was a great degree of variance in the level of glycaemic control and majority (64.6%) had poor or very poor glycaemic control as reflected by their HbA1c levels. The IMA (Mean ± SEM) levels were found to be higher (62.9 ± 1.7ABSU) in the patients with poor glycaemic control compared to those with good glycaemic control (54.2 ± 3.5 ABSU, p-value < 0.05) and correlated with HbA1c levels (r(2)=0.14). IMA levels also appeared to be related with the changes in lipid profile and increased with increasing total cholesterol levels. The subjects with macro-vascular complications (retinopathy and neuropathy) showed non-significantly higher levels of IMA. The elevation in IMA correlated with the HbA1c and changes in the lipid profile.
CONCLUSION: IMA correlates with poor glycaemic control and dyslipidaemia associated with T2 DM and could serve as an indicator of oxidant stress in these patients.

Entities:  

Keywords:  Dyslipidaemia; HbA1c; Oxidant Stress

Year:  2016        PMID: 27134857      PMCID: PMC4843243          DOI: 10.7860/JCDR/2016/15282.7432

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  15 in total

1.  Novel inflammatory markers of coronary risk: theory versus practice.

Authors:  P Libby; P M Ridker
Journal:  Circulation       Date:  1999-09-14       Impact factor: 29.690

2.  The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde.

Authors:  Adem Turk; Irfan Nuhoglu; Ahmet Mentese; Süleyman Caner Karahan; Hidayet Erdol; Cihangir Erem
Journal:  Retina       Date:  2011-03       Impact factor: 4.256

3.  Diagnosis of ischemic heart disease using CK-MB, troponin-I and ischemia modified albumin.

Authors:  Jelal Dawie; Ragender Chawla; Yeshak Worku; Aklilu Azazh
Journal:  Ethiop Med J       Date:  2011-01

4.  Is the measurement of serum ischemia-modified albumin the best test to diagnose ovarian torsion?

Authors:  Suleyman Guven; Cavit Kart; Emine Seda Guvendag Guven; Esra Can Cetin; Ahmet Menteşe
Journal:  Gynecol Obstet Invest       Date:  2015-01-09       Impact factor: 2.031

Review 5.  Assessment and monitoring of glycemic control in primary diabetes care: monitoring techniques, record keeping, meter downloads, tests of average glycemia, and point-of-care evaluation.

Authors:  Ali A Rizvi; Michelle B Sanders
Journal:  J Am Acad Nurse Pract       Date:  2006-01

6.  Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus.

Authors:  Michelle Kaefer; Sílvia J Piva; José A M De Carvalho; Dievan B Da Silva; Aline M Becker; Adriane C Coelho; Marta M M F Duarte; Rafael N Moresco
Journal:  Clin Biochem       Date:  2009-12-05       Impact factor: 3.281

7.  Relation of increased hemoglobin A(1c) levels to severity of peripheral arterial disease in patients with diabetes mellitus.

Authors:  Wilbert S Aronow; Chul Ahn; Melvin B Weiss; Sateesh Babu
Journal:  Am J Cardiol       Date:  2007-04-05       Impact factor: 2.778

8.  Ischemia modified albumin: A novel marker for acute coronary syndrome.

Authors:  R Chawla; Navendu Goyal; Rajneesh Calton; Shweta Goyal
Journal:  Indian J Clin Biochem       Date:  2006-03

9.  Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease.

Authors:  Shao-gang Ma; Chun-ling Wei; Bing Hong; Wei-nan Yu
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report.

Authors:  Agnieszka Piwowar; Maria Knapik-Kordecka; Maria Warwas
Journal:  Dis Markers       Date:  2008       Impact factor: 3.434

View more
  1 in total

Review 1.  Ischemia-Modified Albumin: Origins and Clinical Implications.

Authors:  Alla Shevtsova; Iuliia Gordiienko; Viktoriia Tkachenko; Galyna Ushakova
Journal:  Dis Markers       Date:  2021-07-19       Impact factor: 3.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.